GBP2 is a prognostic biomarker and associated with immunotherapeutic responses in gastric cancer

[1]  Yongmei Yin,et al.  Protocol to identify novel immunotherapy biomarkers based on transcriptomic data in human cancers , 2023, STAR protocols.

[2]  Bin Liu,et al.  GBP2 promotes clear cell renal cell carcinoma progression through immune infiltration and regulation of PD‑L1 expression via STAT1 signaling , 2023, Oncology reports.

[3]  Xiaobo Fan,et al.  Clinical application and detection techniques of liquid biopsy in gastric cancer , 2023, Molecular Cancer.

[4]  Yongmei Yin,et al.  SECTM1 is upregulated in immuno-hot tumors and predicts immunotherapeutic efficacy in multiple cancers , 2023, iScience.

[5]  Ran Wei,et al.  The significance of glycolysis in tumor progression and its relationship with the tumor microenvironment , 2022, Frontiers in Pharmacology.

[6]  V. Apostolopoulos,et al.  Cancer Immunotherapy: The Checkpoint between Chronic Colitis and Colorectal Cancer , 2022, Cancers.

[7]  M. Kanehisa,et al.  KEGG for taxonomy-based analysis of pathways and genomes , 2022, Nucleic Acids Res..

[8]  Xuehai Wang,et al.  Statin shapes inflamed tumor microenvironment and enhances immune checkpoint blockade in non–small cell lung cancer , 2022, JCI insight.

[9]  Tonglian Wang,et al.  Sangerbox: A comprehensive, interaction‐friendly clinical bioinformatics analysis platform , 2022, iMeta.

[10]  Jie Mei,et al.  HLA class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC , 2022, BMC cancer.

[11]  Q. Lan,et al.  GBP3 promotes glioblastoma resistance to temozolomide by enhancing DNA damage repair , 2022, Oncogene.

[12]  L. Pusztai,et al.  Predictive markers of response to neoadjuvant durvalumab with nab-paclitaxel and dose dense doxorubicin/cyclophosphamide in basal-like triple negative breast cancer. , 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  Jing Liu,et al.  Subtyping of microsatellite stability colorectal cancer reveals guanylate binding protein 2 (GBP2) as a potential immunotherapeutic target , 2022, Journal for ImmunoTherapy of Cancer.

[14]  Yun Cai,et al.  Interferon-Induced Transmembrane Protein 3 Shapes an Inflamed Tumor Microenvironment and Identifies Immuno-Hot Tumors , 2021, Frontiers in Immunology.

[15]  G. Mayhew,et al.  Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience , 2021, British Journal of Cancer.

[16]  Dihua Yu,et al.  Tumor microenvironment as a therapeutic target in cancer. , 2020, Pharmacology & therapeutics.

[17]  D. Fox,et al.  Interferon-stimulated GTPases in autoimmune and inflammatory diseases: promising role for the guanylate-binding protein (GBP) family. , 2020, Rheumatology.

[18]  Young-Joon Kim,et al.  Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer , 2020, Experimental & Molecular Medicine.

[19]  Huiyu Wang,et al.  BRCA1 Is a Novel Prognostic Indicator and Associates with Immune Cell Infiltration in Hepatocellular Carcinoma. , 2020, DNA and cell biology.

[20]  Junnian Zheng,et al.  Turning Cold into Hot: Firing up the Tumor Microenvironment. , 2020, Trends in cancer.

[21]  Q. Lan,et al.  GBP2 enhances glioblastoma invasion through Stat3/fibronectin pathway , 2020, Oncogene.

[22]  J. Rathmell,et al.  Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy. , 2020, Molecular cell.

[23]  Xiaole Shirley Liu,et al.  TIMER2.0 for analysis of tumor-infiltrating immune cells , 2020, Nucleic Acids Res..

[24]  S. Malhotra,et al.  Guanylate-Binding Protein 1: An Emerging Target in Inflammation and Cancer , 2020, Frontiers in Immunology.

[25]  L. Kennedy,et al.  A review of cancer immunotherapy toxicity , 2020, CA: a cancer journal for clinicians.

[26]  Yichao Zhu,et al.  Overexpressed DAAM1 correlates with metastasis and predicts poor prognosis in breast cancer. , 2019, Pathology, research and practice.

[27]  Minoru Kanehisa,et al.  Toward understanding the origin and evolution of cellular organisms , 2019, Protein science : a publication of the Protein Society.

[28]  P. Maini,et al.  The Goldilocks Window of Personalized Chemotherapy: Getting the Immune Response Just Right. , 2019, Cancer research.

[29]  K. Tretina,et al.  Interferon-induced guanylate-binding proteins: Guardians of host defense in health and disease , 2019, The Journal of experimental medicine.

[30]  J. Schellens,et al.  Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  J. Madore,et al.  Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy. , 2019, Cancer cell.

[32]  Y. Miyagi,et al.  Identification of a high‐risk subtype of intestinal‐type Japanese gastric cancer by quantitative measurement of the luminal tumor proportion , 2018, Cancer medicine.

[33]  Joon-Oh Park,et al.  Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer , 2018, Nature Medicine.

[34]  Jing Wang,et al.  LinkedOmics: analyzing multi-omics data within and across 32 cancer types , 2017, Nucleic Acids Res..

[35]  M. M. Dias,et al.  Guanylate-binding protein-1 is a potential new therapeutic target for triple-negative breast cancer , 2017, BMC Cancer.

[36]  D. Schadendorf,et al.  Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma , 2017, The New England journal of medicine.

[37]  Yan Li,et al.  The tumor-stromal ratio as a strong prognosticator for advanced gastric cancer patients: proposal of a new TSNM staging system , 2017, Journal of Gastroenterology.

[38]  Dakeun Lee,et al.  Intratumor stromal proportion predicts aggressive phenotype of gastric signet ring cell carcinomas , 2017, Gastric Cancer.

[39]  K. Lan,et al.  Guanylate-Binding Protein 1 Inhibits Nuclear Delivery of Kaposi's Sarcoma-Associated Herpesvirus Virions by Disrupting Formation of Actin Filament , 2017, Journal of Virology.

[40]  Ying Zhu,et al.  Inducible GBP5 Mediates the Antiviral Response via Interferon-Related Pathways during Influenza A Virus Infection , 2017, Journal of Innate Immunity.

[41]  Pornpimol Charoentong,et al.  Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade , 2016, bioRxiv.

[42]  J. Rahnenführer,et al.  Interferon-inducible guanylate binding protein (GBP2) is associated with better prognosis in breast cancer and indicates an efficient T cell response , 2014, Breast Cancer.

[43]  Helga Thorvaldsdóttir,et al.  Molecular signatures database (MSigDB) 3.0 , 2011, Bioinform..

[44]  D. Vestal,et al.  The guanylate-binding proteins: emerging insights into the biochemical properties and functions of this family of large interferon-induced guanosine triphosphatase. , 2011, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[45]  D. Sargent,et al.  Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. , 2010, JAMA.

[46]  G. Kochs,et al.  Interferon-induced Mx proteins in antiviral host defense. , 2007, Biochimie.

[47]  M. Vieth,et al.  GBP-1 acts as a tumor suppressor in colorectal cancer cells. , 2013, Carcinogenesis.

[48]  Hiroyuki Ogata,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 1999, Nucleic Acids Res..

[49]  H. Espejo,et al.  [Gastric cancer]. , 1996, Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru.